The July 9 disclosure triggered a sharp market reaction, shaving $10.79 off the price of each American Depositary Share and leaving them at $187.49. The failed trial, conducted in partnership with Ionis Pharmaceuticals, was intended to validate Wainua as a primary therapy for amyloid cardiomyopathy. Investors who held stock during this period are now being encouraged by legal counsel to come forward as the firm evaluates potential securities fraud and breaches of fiduciary duty.
Pomerantz LLP, a firm with a global footprint spanning London, Paris, and Tel Aviv, is currently spearheading the inquiry. While the firm has a long history of securing multimillion-dollar settlements in corporate litigation, they note that previous successes remain independent of the outcome here. Any individuals impacted by the decline in AstraZeneca’s market value are directed to contact Danielle Peyton to discuss the potential for a class-action filing.
Comments (0)
No comments yet. Be the first!